Camrelizumab,rivoceranib,temozolomide 
jiangsu hengrui pharmaceuticals,hlb bio group,orphelia pharmaceuticals
['camrelizumab', 'melanoma', 'triplet']
#melanoma orals #asco22:
new triplet combo camrelizumab+apatinib+temodar showed orr of 66.7% for metastatic pts with acral melanoma, safety data reassuring! 
Hematology and Medical Oncology fellow at Duke University, Lebanese, husband to the best anesthesiologist, IO fan, trialist and skin cancer specialist to be!